Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma by 藤澤 康弘 et al.
Serum Level of Soluble CD163 May Be a
Predictive Marker of the Effectiveness of
Nivolumab in Patients With Advanced Cutaneous
Melanoma
著者（英） Taku Fujimura, Yota Sato, Kayo Tanita, Yumi
Kambayashi, Atsushi Otsuka, Yasuhiro FUJISAWA,
Koji Yoshino, Shigeto Matsushita, Takeru
Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi
Uchi, Yumi Nonomura, Ryota Tanaka, Megumi
Aoki, Keisuke Imafuku, Hisako Okuhira, Naoko
Wada, Hiroyuki Irie, Takanori Hidaka, Akira
Hashimoto, Setsuya Aiba
journal or
publication title
Frontiers in Oncology
volume 8
page range 530
year 2018-11
権利 (C) 2018 Fujimura, Sato, Tanita, Kambayashi,
Otsuka, Fujisawa, Yoshino, Matsushita,
Funakoshi, Hata, Yamamoto, Uchi, Nonomura,
Tanaka, Aoki, Imafuku, Okuhira, Wada, Irie,
Hidaka, Hashimoto and Aiba. This is an
open-access article distributed under the
terms of the Creative Commons Attribution
License (CC BY). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited,
in accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms. 
URL http://hdl.handle.net/2241/00157227
doi: 10.3389/fonc.2018.00530
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
ORIGINAL RESEARCH
published: 19 November 2018
doi: 10.3389/fonc.2018.00530
Frontiers in Oncology | www.frontiersin.org 1 November 2018 | Volume 8 | Article 530
Edited by:
Marie-France Penet,
School of Medicine, Johns Hopkins
University, United States
Reviewed by:
Ellen Ackerstaff,
Memorial Sloan Kettering Cancer
Center, United States
Goutam Chakraborty,
Memorial Sloan Kettering Cancer
Center, United States
Tone Frost Bathen,
Norwegian University of Science and
Technology, Norway
*Correspondence:
Taku Fujimura
tfujimura1@mac.com
Specialty section:
This article was submitted to
Cancer Imaging and Diagnosis,
a section of the journal
Frontiers in Oncology
Received: 30 June 2018
Accepted: 30 October 2018
Published: 19 November 2018
Citation:
Fujimura T, Sato Y, Tanita K,
Kambayashi Y, Otsuka A, Fujisawa Y,
Yoshino K, Matsushita S, Funakoshi T,
Hata H, Yamamoto Y, Uchi H,
Nonomura Y, Tanaka R, Aoki M,
Imafuku K, Okuhira H, Wada N, Irie H,
Hidaka T, Hashimoto A and Aiba S
(2018) Serum Level of Soluble CD163
May Be a Predictive Marker of the
Effectiveness of Nivolumab in Patients
With Advanced Cutaneous
Melanoma. Front. Oncol. 8:530.
doi: 10.3389/fonc.2018.00530
Serum Level of Soluble CD163 May
Be a Predictive Marker of the
Effectiveness of Nivolumab in
Patients With Advanced Cutaneous
Melanoma
Taku Fujimura 1*, Yota Sato 1, Kayo Tanita 1, Yumi Kambayashi 1, Atsushi Otsuka 2,
Yasuhiro Fujisawa 3, Koji Yoshino 4, Shigeto Matsushita 5, Takeru Funakoshi 6, Hiroo Hata 7,
Yuki Yamamoto 8, Hiroshi Uchi 9, Yumi Nonomura 2, Ryota Tanaka 3, Megumi Aoki 5,
Keisuke Imafuku 7, Hisako Okuhira 8, Naoko Wada 9, Hiroyuki Irie 2, Takanori Hidaka 1,
Akira Hashimoto 1 and Setsuya Aiba 1
1Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Department of Dermatology,
Kyoto University Graduate School of Medicine, Kyoto, Japan, 3Department of Dermatology, Faculty of University of Tsukuba,
Tsukuba, Japan, 4Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome
Hospital, Tokyo, Japan, 5Department of Dermato-Oncology, Dermatology, National Hospital Organization Kagoshima Medical
Center, Kagoshima, Japan, 6Department of Dermatology, Keio University School of Medicine, Tokyo, Japan, 7Department of
Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 8Department of Dermatology, Wakayama
Medical University, Wakayama, Japan, 9Department of Dermatology, Kyushu University Graduate School of Medicine,
Fukuoka, Japan
Antibodies against programmed cell death protein 1, such as nivolumab and
pembrolizumab, are widely used for treating various cancers, including advanced
melanoma. Nivolumab significantly prolongs survival in patients with metastatic
melanoma, and sequential administration with lipilimumab may improve outcomes when
switched at the appropriate time. Biomarkers are therefore needed to evaluate nivolumab
efficacy soon after first administration. This study analyzed serum levels of soluble
cluster of differentiation 163 (sCD163) in 59 cases of advanced cutaneous melanoma
and 16 cases of advanced mucosal melanoma treated using nivolumab. Serum levels
of sCD163 were significantly increased after 6 weeks in responders compared to
non-responders after initial administration of nivolumab for cutaneous melanoma. In
contrast, no significant difference between responders and non-responders was seen
among patients with non-cutaneous melanoma. These results suggest that sCD163 may
be useful as a biomarker for selecting patients with advanced cutaneous melanomamost
likely to benefit from anti-melanoma immunotherapy.
Keywords: sCD163, TAMs, melanoma, nivolumab, prediction of efficacy
INTRODUCTION
The programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway
plays a critical role in tumor immune response. Anti-PD-1 antibodies such as nivolumab
and pembrolizumab are thus in wide use for the treatment of various cancers, including
advanced melanoma (1, 2). Nivolumab significantly prolongs survival in patients with metastatic
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melanoma (1), and co-administration with ipilimumab also
leads to improved outcomes (1–3). Ipilimumab is a fully
humanized immunoglobulin (Ig)G1 monoclonal antibody that
blocks cytotoxic T-lymphocyte antigen (CTLA-4) to activate and
increase T cells, and suppress the function of regulatory T cells
(Tregs) (4). Previous reports have suggested ipilimumab is useful
for treating advanced melanoma, particularly in combination
with other anti-melanoma reagents (1–3, 5). Moreover,
combination therapy using nivolumab and ipilimumab
reportedly increases the response rate for untreated metastasis of
melanoma to the brain (6). However, the efficacy of ipilimumab
in patients with nivolumab-resistant melanoma is extremely
low after objective tumor progression (7). Because both co-
administration of nivolumab and ipilimumab and sequential
administration of nivolumab and ipilimumab with a planned
switch leads to a high frequency of immune-related adverse
events (irAEs) in patients with advanced melanoma (1, 3),
determining the efficacy of nivolumab monotherapy before the
planned switch from nivolumab to ipilimumab is important.
Tumor-associated macrophages (TAMs) are characterized
by their heterogeneity and plasticity, and may be functionally
reprogrammed to polarized phenotypes by exposure to cancer-
related factors, stromal factors, or infection, leading to the
production of various chemokines that play significant roles
in maintaining the tumor microenvironment (8–13). Because
PD-1 expression in TAMs is one of the key factors in M2
macrophage polarization (14), administration of an anti-PD1
antibody might repolarize TAMs, leading to TAM activation in
melanoma patients. Because the main population of TAMs in
skin cancer is CD163+ M2 macrophages, and soluble cluster of
differentiation 163 (sCD163) is a TAMmarker that appears in the
serum as a result of proteolytic shedding (15), we hypothesized
that serum sCD163 may offer a predictive marker for the efficacy
of nivolumab in the early stage of disease. This study analyzed
serum levels of sCD163 in 59 cases of advanced cutaneous
melanoma and 16 cases of advanced mucosal melanoma treated
with nivolumab.
PATIENTS AND METHODS
Ethics Statement For Human Experiments
The protocol for this human study was approved by the
ethics committee of Tohoku University Graduate School of
Medicine, Sendai, Japan (Permit No: 2017-1-064). All methods
were performed in accordance with the relevant guidelines and
regulations. All patients provided written informed consent.
Patients
Data from patients treated with nivolumab were collected from
eight clinical sites in Japan. Patients were eligible if they had
unresectable stage III melanoma, the tumor was resectable but
the patient had declined resection, or if the patient had stage
IV melanoma with accessible cutaneous, subcutaneous, and/or
nodal lesions (staging was performed according to the AJCC
Staging Manual, 7th edition, 2011). All patients received 2 mg/kg
of nivolumab followed by a 3-week rest period or 3 mg/kg
of nivolumab followed by 2 weeks of rest, both of which are
approved dosing schedules in Japan. Serum from patients was
obtained on days 0 and 42.
Serum Levels of sCD163
On days 0 and 42 after nivolumab administration, we stored the
serum and analyzed serum levels of soluble sCD163 by enzyme-
linked immunoassay (ELISA) according to the protocol provided
by the manufacturer (catalog number DY1607; R&D Systems,
Minneapolis, MN). Data from each donor were obtained as the
mean of duplicate assays. Serum levels on day 42 were compared
to baseline (day 0) and statistically analyzed.
Statistical Methods
Receiver operating characteristic (ROC) curves were applied
to calculate cut-off values for serum levels of sCD163 and
areas under the curve (AUCs). Cut-offs were determined using
Youden’s index (16) (sensitivity + specificity −1) to determine
the point of maximum index value. ROC curves were established
to evaluate serum levels of sCD163 in patients administered
nivolumab. For a single comparison between two groups, the
Mann-Whitney U-test was used. Levels of significance were set
at p < 0.01. All statistical analyses were performed using JMP
version 14.1 software (SAS Institute, Tokyo, Japan).
RESULTS
Patients
We collected data from 75 melanoma patients treated with
nivolumab, including 59 patients with cutaneous melanoma
(Table 1) and 16 patients with non-cutaneous (e.g., digestive
tract, vagina, nasal cavity) melanoma (Table 2). Mean patient age
was 68.0 years for cutaneous melanoma (range, 31–93 years) and
66.0 years for non-cutaneous melanoma (range, 54–82 years).
The percentages of male patients with cutaneous and non-
cutaneous melanoma were 57.6 and 56.3%, respectively. The
most common primary tumor site was the extremities (55.9%),
followed by the head and neck (15.3%), trunk (11.9%), mucosal
origin (8.5%), and unknown origin (8.5%).
Efficacy of Nivolumab at 3 Months After
First Administration
Among patients with cutaneous melanoma, complete response
(CR) was seen in 1 patient (1.7%; 95% confidence interval [CI],
0–3.4%), partial response (PR) in 12 patients (20.3%; 95%CI,
0–40.6%), stable disease (SD) in 16 patients (27.1%; 95%CI,
0–54.2%), and progressive disease (PD) in 29 patients (49.2%;
95%CI, 0–98.4%). The objective response rate (ORR) at 3 months
after first administration was thus 22.0% (95%CI, 0–44.0%).
Tumor responses of individual patients are listed in Table 1.
Among patients with mucosal melanoma, PR was seen in 4
patients (25.0%; 95%CI, 0–50.0%), SD in 5 patients (31.3%;
95%CI, 0–62.6%), and PD in 7 patients (43.8%; 95%CI, 0–87.6%).
The ORR at 3 months after first administration was thus 25.0%
(95%CI, 0–50.0%). Tumor responses of individual patients are
listed in Table 2.
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TABLE 1 | Characteristics and serum levels of sCD163 in patients with cutaneous melanoma.
Age (y) Sex Location Body weight
(kg)
Prior systemic
therapy
Efficacy at
3 months
Increase of
sCD163
Change ratio
of sCD163 (%)
No. 1 61–70 M Extremities 63.2 DAV+IFN-β PR 11.556 149
No. 2 61–70 M Extremities 48 – PR 50.8525 227.8
No. 3 81–90 F Extremities 48.7 DPCP PR 12.676 152.7
No. 4 61–70 M Extremities 70.4 DAV+IFN-β PR 13.27122 146.2
No. 5 61–70 M Extremities 58.5 DAV+IFN-β PR 7.17709 127
No. 6 61–70 M Lip 69.8 DAV+IFN-β PR 5.834 123.1
No. 7 71–80 M Trunk 59.4 – PR 21.49956 133.4
No. 8 71–80 F Extremities 68 – PR −12.9704 81.6
No. 9 31–40 F Extremities 55.4 DTIC+IFN-β PR 24.5042321 189.5
No. 10 71–80 M Extremities 61.2 – PR 3.36944 109.5
No. 11 51–60 F Extremities 41.7 – CR 2.109187 170.7
No. 12 81–90 M Unknown 68.3 – PR 3.07118 111.3
No. 13 71–80 F Extremities 50.1 IFN-α PR 35.7011169 158.5
No. 1 51–60 M Trunk 68.7 – SD 1.5625 107.5
No. 2 31–40 F Extremities 60.8 CBDCA+PTX PD −9.6755 82.4
No. 3 61–70 M Trunk 62 DTIC+IFN-β PD 2.884 109.6
No. 4 81–90 F Extremities 44.9 IFN-α PD −0.333 98.7
No. 5 71–80 M Head and neck 59.2 IFN-β SD 0.998 103.6
No. 6 81–90 F Trunk 41.9 IFN-β PD 6.76453 116.9
No. 7 91–100 M Extremities 55 IFN-β PD 4.02405 113
No. 8 71–80 M Extremities 85.9 IFN-β SD −5.10307 89.9
No. 9 31–40 M Extremities 73 TMZ PD −16.806 67.8
No. 10 61–70 M Extremities 55 anti-CCR4 Abs PD 2.706 115.4
No. 11 61–70 F Extremities 66.3 DAV+IFNβ PD 0.653 103.4
No. 12 61–70 M Head and neck 55 DTIC PD −0.094 99.6
No. 13 61–70 M Extremities 115.4 DAV+IFN-β SD 0.177 100.5
No. 14 61–70 M Extremities 77.6 IFN-β PD −61.59461 35.5
No. 15 81–90 F Unknown 47.8 – SD −6.54815 86.5
No. 16 71–80 M Extremities 54.4 IFN-β SD −4.74553 80.8
No. 17 61–70 F Trunk 46.5 – PD 17.3346 140.4
No. 18 71–80 M Extremities 53.7 – PD −1.595225 93
No. 19 51–60 F Head and neck 49.2 DTIC+IFN-β PD 5.457395 115.9
No. 20 31–40 M Trunk 78.8 IFN-α SD −12.615365 53.7
No. 21 61–70 F Trunk 48.8 IFN-β PD −1.7178157 96.2
No. 22 31–40 F Head and neck 52.3 IFN-β PD 3.88229 120.1
No. 23 71–80 F External genitalia 59.1 – SD −3.34502 92.1
No. 24 71–80 F External genitalia 53.4 IFN-β SD −7.38773 70.5
No. 25 61–70 F Extremities 47.0 – PD −4.11263 64
No. 26 61–70 M Unknown 53.6 – PD −3.78005 75.6
No. 27 61–70 F Extremities 60.9 IFN-β PD −0.54818 95.9
No. 28 61–70 F Head and neck 41.6 IFN-α PD −1.456879 80.8
No. 29 71–80 M Trunk 56 – PD −0.71335 77.2
No. 30 41–50 F External genitalia 69.2 – PD −0.170996 94.4
No. 31 71–80 F Extremities 53.3 – PD −0.682222 85.8
No. 32 61–70 M Extremities 61 – SD 2.202349 183.2
No. 33 71–80 M Unknown 55 – PD 0.328041 107.4
No. 34 61–70 F Extremities 68 – SD 0.228017 106.3
No. 35 71–80 M Extremities 59.3 IFN-β SD −1.7178157 96.2
No. 36 61–70 M Unknown 49.1 – PD 0.428485 117.4
No. 37 61–70 M Head and neck 61 – SD 0.164125 110.7
(Continued)
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TABLE 1 | Continued
Age (y) Sex Location Body weight
(kg)
Prior systemic
therapy
Efficacy at
3 months
Increase of
sCD163
Change ratio
of sCD163 (%)
No. 38 41–50 F External genitalia 56 – SD 1.268748 247.2
No. 39 71–80 F Extremities 47 – PD −0.721186 86.1
No. 40 41–50 M Head and neck 103 DTIC PD −0.111639 98
No. 41 61–70 M Extremities 73 IFN-β SD 0.421323 113.8
No. 42 31–40 M Extremities 63.5 – PD 0.9897167 102.1
No. 43 71–80 F Extremities 66.2 – SD 7.3643392 116.5
No. 44 71–80 M Extremities 63.7 IFN-β PD −7.0989841 91.9
No. 45 71–80 M Head and neck 57.4 – PD −0.5957191 98.4
No. 46 41–50 M Extremities 62.7 IFN-β PD 2.4247196 105.7
CBDCA, carboplatin; PTX, paclitaxel; DTIC; dacarbazine; TMZ, temozolomide; DAV, dacarbazine + nimustine hydrochloride + vincristine. Serum level changes of sCD163 from each
patient (n = 59) between day 42 and day 0 were examined by ELISA. Data for each donor represent the means of duplicate assays.
TABLE 2 | Characteristics and serum levels of sCD163 in patients with non-cutaneous melanoma.
Age (y) Sex Location Body weight
(kg)
Prior systemic
therapy
Efficacy at
3 months
Increase of
sCD163
Change ratio
of sCD163 (%)
No. 1 61–70 M Digestive duct 62 – PR −0.444523 81.5
No. 2 61–70 F Palate 52.8 – PR −0.799493 77.6
No. 3 61–70 M Paranasal 71 – PR −1.803397 62.8
No. 4 61–70 F Vagina 52.5 – PR 0.469173 114.6
No. 1 61–70 M Vagina 53.4 – SD −17.52087 78.7
No. 2 61–70 M Vagina 80.4 – PD 49.95895 134.6
No. 3 51–60 F Conjunctiva 84 – SD 8.27076 115.4
No. 4 81–90 M Digestive duct 49.5 – PD 19.6379 158.1
No. 5 61–70 F Digestive duct 49.3 – SD 20.26377 155.2
No. 6 71–80 F Vagina 50.1 – PD 28.525981 192.1
No. 7 61–70 M Nasal cavity 47.2 DTIC PD 17.0558 132.6
No. 8 61–70 F Vagina 53.1 DAV + IFN-β PD −17.787 64.2
No. 9 61–70 M Paranasal 56 DTIC PD 0.16109 132.6
No. 10 51–60 M Palate 52.9 – PD 1.086 107.3
No. 11 71–80 M Nasal cavity 53.1 DAV + IFN-β SD 2.52838 107.6
No. 12 71–80 F Nasal cavity 53 – SD −0.345647 89.4
DAV, dacarbazine + nimustine hydrochloride + vincristine; DTIC, dacarbazine Serum level changes of sCD163 from each patient (n = 16) between day 42 and day 0 were examined
by ELISA. Data for each donor represent the means of duplicate assays.
Serum Levels of sCD163
To determine whether serum levels of sCD163 may predict
early response in melanoma patients treated with nivolumab,
we evaluated levels in 75 patients with advanced melanoma
treated using nivolumab (Supplemental Figure 1). Compared
to baseline (day 0), serum levels of sCD163 at day 42
were significantly increased in the group showing objective
response (p < 0.0001; Figure 1A) among patients with advanced
cutaneous melanoma, whereas no significant difference in
serum sCD163 levels was seen among patients with advanced
mucosal melanoma (Figure 2A). Increases in serum sCD163
and efficacy at 3 months after the first administration of
nivolumab in each patient are described in Tables 1, 2. The
thresholds for sCD163 change between day 42 and day 0 to
distinguish responders from non-responders were respectively
3.07 ± 0.07 ng/mL and 0.47 ± 0.05 ng/mL in cutaneous and
non-cutaneous melanoma. In the cutaneous melanoma cohort,
the mean change ratio in sCD163 serum level was 144.6% for
those patients showing objective response, compared to 101.0%
for non-responders (Table 1). In the mucosal melanoma cohort,
the mean change ratio in sCD163 serum level was 84.1% for
those patients showing objective response, and 122.3% for non-
responders (Table 2). The threshold for increased serum sCD163
in cutaneous melanoma was 3.07 ± 0.07 ng/mL, whereas that in
non-cutaneousmelanoma was 0.47± 0.05 ng/mL. The sensitivity
and specificity of serum sCD163 in cutaneous melanoma were
84.6 and 87.0%, respectively (p = 0.0030; Figure 1B), whereas
the sensitivity and specificity of serum sCD163 in non-cutaneous
melanoma were 100 and 66.7%, respectively (p = 0.3154;
Figure 2B).
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FIGURE 1 | Serum levels of sCD163 and ROC curve in cutaneous melanoma. Serum level changes of sCD163 in each patient (n = 59) (A) on day 42. The ROC curve
was applied to calculate cut-offs for sCD163 serum levels and AUC (B). Cut-offs were determined to distinguish responders from nonresponders using Youden’s index.
FIGURE 2 | Serum levels of sCD163 and ROC curve in non-cutaneous melanoma. Serum level changes of sCD163 in each patient (n = 16) (A) on day 42. The ROC
curve was applied to calculate cut-offs for sCD163 serum levels and AUC (B). Cut-offs were determined to distinguish responders from nonresponders using
Youden’s index.
DISCUSSION
Because nivolumab shows higher efficacy than other anti-
melanoma drugs (e.g., ipilimumab and dacarbazine) (1, 17),
and induces a longer duration of anti-tumor response
than BRAF/MEK inhibitors (e.g., vemurafenib, dabrafenib,
trametinib) (18, 19), oncologists have been particularly interested
in combining nivolumab with agents that enhance anti-tumor
immune responses in patients with metastatic melanoma (1–
3, 20). The efficacy of nivolumab appears significantly increased
when combined with ipilimumab (57.7%), but the rate of severe
treatment-related AEs (Grade 3 or 4) is unfortunately also
significantly increased with this particular combination (59.0%)
(1, 2). To avoid severe AEs caused by ipilimumab, predictive
biomarkers are needed to evaluate the efficacy of nivolumab
monotherapy at 2–3 months after first administration, to prepare
for any planned switch from nivolumab to ipilimumab.
CD163 is a member of the scavenger receptor cysteine-
rich family, and is exclusively expressed on cells of the
monocyte/macrophage lineage (15). As previously reported, in
metastatic melanoma, a substantial number of CD163+ TAMs
are present in metastatic melanoma and are activated by stromal
factors, leading to an increase in serum levels of sCD163 as
a result of proteolytic shedding (21–23). In addition, Jensen
et al. (21) previously reported sCD163 and CD163+ TAMs
as a prognostic marker for early-stage cutaneous melanoma.
Notably, as Gordon et al. (14) reported, PD-1 expression is a
key factor in maintaining TAMs as M2-polarized, and blockade
of PD-1/PD-L1 leads to conversion of TAMs into M1-polarized
activated macrophages. Because TAMs in melanoma comprise a
heterogeneous, mainly immunosuppressive population (9, 23),
and because repolarization of TAMs into the activated subtype
by immunomodulatory drugs has been reported to significantly
suppress melanoma growth in a spontaneous mouse melanoma
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model (8), we hypothesized that one of the targets for nivolumab
in melanoma is activated CD163+ TAMs.
To prove our hypothesis, we analyzed serum levels of sCD163
in 59 cases of advanced cutaneous melanoma and 16 cases of
advanced mucosal melanoma treated with nivolumab. Serum
levels of sCD163 were significantly increased 6 weeks after
initial administration of nivolumab in the response group
compared to the non-response group in cutaneous melanoma. In
contrast, no significant difference between nivolumab responders
and non-responders was seen for non-cutaneous melanoma.
Interestingly, in non-cutaneous melanoma, serum levels of
sCD163 in non-responders tended to be even higher than
those in responders. This discrepancy might be explained by
differences in cancer stroma that could stimulate TAMs in the
tumor microenvironment of each organ. Such studies should be
performed in the future.
According to the present results, sCD163 may represent a
predictive biomarker for evaluating the efficacy of nivolumab
at 3 months after first administration for advanced cutaneous
melanoma. Because sequential administration of ipilimumab
followed by nivolumab is only effective for advanced melanoma
before the melanoma develops tolerance for nivolumab (7),
and administration of ipilimumab leads to the development of
irAEs more frequently than nivolumab (2, 3), predicting the
efficacy of nivolumab before first tumor estimation is crucial
to determining whether the patient will successfully adapt to
the planned switch from nivolumab to ipilimumab therapy. The
present study suggested that sCD163 may be a useful biomarker
for the selection of those cutaneous melanoma patients most
likely to benefit from anti-melanoma immunotherapy using
nivolumab and ipilimumab. Because this was a pilot study, future
independent studies with larger patient cohorts are needed to
confirm our findings.
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